InvestSMART

Cyclopharm Limited (ASX: CYC) - Announcements

- Current share price for CYC : $0.480

ASX company news and announcements for Cyclopharm Limited (CYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cyclopharm Limited (CYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cyclopharm Limited (CYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cyclopharm Limited (CYC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$60 Technegas US Momentum Accelerates with $US1m Sales Milestone 1 Apr 2025 9:51AM $1.150 $0.480 fallen by 58.26%
$60 Appendix 4G & Corporate Governance Statement 27 Mar 2025 2:11PM $1.150 $0.480 fallen by 58.26%
$60 Annual Report to shareholders 27 Mar 2025 2:11PM $1.150 $0.480 fallen by 58.26%
$60 CYC to present at NWR Virtual Healthcare Conference 19 Mar 2025 2:53PM $1.440 $0.480 fallen by 66.67%
$60 Company Update 19 Mar 2025 10:12AM $1.425 $0.480 fallen by 66.32%
$60 Webinar - Cyclopharm Business Update 17 Mar 2025 10:56AM $1.430 $0.480 fallen by 66.43%
$60 CYC signs 5-year Agreement with USA Veterans Administration 14 Mar 2025 8:20AM $1.430 $0.480 fallen by 66.43%
$60 Date of Annual General Meeting 10 Mar 2025 4:03PM $1.405 $0.480 fallen by 65.84%
$60 Change of Director's Interest Notice - DH 26 Feb 2025 1:38PM $1.475 $0.480 fallen by 67.46%
$60 Change of Director's Interest Notice - JW 26 Feb 2025 1:02PM $1.470 $0.480 fallen by 67.35%
$60 CYC Results Summary 25 Feb 2025 8:03AM $1.900 $0.480 fallen by 74.74%
$60 Preliminary Final Report 25 Feb 2025 8:02AM $1.900 $0.480 fallen by 74.74%
$60 Change in substantial shareholding from AEF 28 Jan 2025 2:44PM $2.350 $0.480 fallen by 79.57%
$60 CYC Signs US National Agreement with HCA for Technegas 23 Jan 2025 8:19AM $2.030 $0.480 fallen by 76.35%
$60 Response to ASX Price Query 6 Jan 2025 3:27PM $1.980 $0.480 fallen by 75.76%
$60 Cyclopharm's USA Technegas Expansion Update 20 Dec 2024 11:06AM $1.510 $0.480 fallen by 68.21%
$60 US Clinical Paper - Technegas for Lung Transplant Evaluation 9 Dec 2024 8:59AM $1.610 $0.480 fallen by 70.19%
$60 First Patients Imaged with Technegas - French Clinical Trial 3 Dec 2024 8:30AM $1.650 $0.480 fallen by 70.91%
$60 CYC Receives First Technegas Orders from US VA Hospitals 27 Nov 2024 3:03PM $1.350 $0.480 fallen by 64.44%
$60 Cyclopharm Bell Potter Healthcare Conference Presentation 19 Nov 2024 8:29AM $1.370 $0.480 fallen by 64.96%
$60 CYC Signs Agreement with VA and First DoD Order Received 3 Oct 2024 10:07AM $1.525 $0.480 fallen by 68.52%
$60 Change of Director's Interest Notice - JW 1 Oct 2024 3:43PM $1.520 $0.480 fallen by 68.42%
$60 Cyclopharm - 2024 First Half Results & USA Expansion Update 3 Sep 2024 9:08AM $1.380 $0.480 fallen by 65.22%
$60 Webinar - 1H2024 Results and USA update 29 Aug 2024 3:30PM $1.350 $0.480 fallen by 64.44%
$60 Cyclopharm 2024 H1 Trading and USA Expansion Update 27 Aug 2024 8:41AM $1.415 $0.480 fallen by 66.08%

76 - 100 of 612 results

Page 4 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.